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a b s t r a c t 
Objectives: Biofilms are structured aggregates of bacteria embedded in a self-produced matrix that de- 
velop in diverse ecological niches. Pathogenic bacteria can form biofilms on surfaces and in tissues, caus- 
ing nosocomial and chronic infections that are difficult to treat. While antibiotics are largely inefficient 
in limiting biofilm formation and expansion, antimicrobial peptides (AMPs) are emerging as alternative 
antibiofilm treatments. In this study, we explore the effect of the newly described AMP TAT-RasGAP 317-326 
on Acinetobacter baumannii, Pseudomonas aeruginosa and Staphylococcus aureus biofilms. 
Methods: Efficiency of TAT-RasGAP 317-326 on biofilms was tested in vitro. Both viability of bacteria con- 
tained in the biofilm as well as biomass of the biofilm were quantified using resazurin and crystal violet 
staining, respectively. The antibiofilm effect of TAT-RasGAP 317-326 was compared with a selection of clas- 
sical antibiotics and AMPs. 
Results: We observe that TAT-RasGAP 317-326 inhibits biofilm formation at concentrations equivalent or 
two times greater than the minimum inhibitory concentration (MIC) of planktonic bacteria. Moreover, 
TAT-RasGAP 317-326 limits the expansion of A. baumannii and P. aeruginosa established biofilms at twice the 
concentration inhibiting biofilm formation. 
Conclusion: These results underscore the potential use of TAT-RasGAP 317-326 against biofilms and encour- 
age further studies in the development of AMPs to treat biofilm-related infections. 
© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial 
Chemotherapy. 
This is an open access article under the CC BY-NC-ND license 

























The emergence of antibiotic resistance is a major threat to pub- 
ic health. Infections caused by multidrug-resistant (MDR) bacteria 
re challenging to treat and lead to disability and even death [1] . 
ne limitation in the development of novel antibiotics is the use of 
ree-living (also called planktonic) bacteria in axenic medium as a 
odel system. This model is not representative of infections, which 
re commonly caused by bacterial aggregates embedded in a self- 
roduced matrix, called biofilms [2] . ∗ Corresponding author. Mailing address: Institute of Microbiology, Department 
f Pathology and Laboratory Medicine, Lausanne University Hospital and University 
f Lausanne, Rue du Bugnon 48, CH-1011 Lausanne, Switzerland. Tel.: + 41 21 314 
5 39. 








213-7165/© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Soc
Y-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) Pathogenic bacteria, including Acinetobacter baumannii, Pseu- 
omonas aeruginosa and Staphylococcus aureus , can form biofilms 
n medical devices implanted in humans, in some tissues (e.g. 
ungs, teeth and skin) and on healthcare surfaces [3] . The re- 
ersible formation of biofilms is triggered by signals such as nutri- 
nt limitation, antibiotic exposure and oxygen availability [2] . Bac- 
eria secrete polysaccharides, DNA and proteins that compose the 
iofilm matrix. The latter forms a scaffold for bacterial attachment 
nd protects bacteria from external insults. Bacteria embedded in 
iofilm develop into heterogeneous bacterial subpopulations that 
trongly differ from planktonic bacteria regarding both their gene 
xpression profile and their functional properties [2] . The combina- 
ion of intrinsic bacterial antibiotic resistance and resistance pro- 
ided by the biofilm structure renders biofilms highly challenging 
o eradicate. Thus, we need alternatives to classical antibiotics to 
reat biofilms, especially when containing MDR pathogens. iety for Antimicrobial Chemotherapy. This is an open access article under the CC 











































































































Antimicrobial peptides (AMPs) are short peptides first described 
s a defence mechanism of living organisms towards a broad range 
f pathogens [4] . While the ability of bacteria to develop resistance 
owards AMPs is debated, MDR bacteria are generally not resistant 
o AMPs and, in many cases, even show increased sensitivity to- 
ards AMPs [5] . Some AMPs, alone or combined with antibiotics, 
fficiently inhibit biofilm formation and can even disrupt mature 
iofilms, making them promising antibiofilm agents [6] . 
TAT-RasGAP 317-326 is a chimeric peptide consisting of the cell- 
ermeable HIV peptide TAT 48-57 linked to a 10-amino acid se- 
uence of the Src Homology 3 Domain (SH3 domain) of p120 
asGAP. TAT-RasGAP 317-326 was first described for its anticancer 
roperties, being able to sensitise cancer cells to anticancer ther- 
pies, directly kill cancer cells and display antimetastatic action 
7] . The mechanism of eukaryotic cell killing by this peptide has 
ecently been uncovered. TAT-RasGAP 317-326 kills cancer cells by 
rst accessing the cytosol through direct translocation across the 
lasma membrane and then interacting with inner leaflet-enriched 
hospholipids, such as phosphatidylserine or phosphatidylinositol 
,5-bisphosphate. This interaction eventually lyses the membrane 
nd causes death of the cells [8] . We showed earlier that TAT- 
asGAP 317-326 can also kill bacteria and that it exerts broad an- 
imicrobial activity both against Gram-positive and Gram-negative 
uman pathogens including A. baumannii, P. aeruginosa and S. au- 
eus [9] . TAT-RasGAP 317-326 shares properties already described in 
ther AMPs, such as an overall positive charge and several argi- 
ine and tryptophan residues. Arginine residues interact with the 
egatively-charged bacterial membrane, while tryptophan residues 
ppear to insert in the bacterial membrane [10] . These interactions 
ay enable AMPs to translocate into the bacteria without disrupt- 
ng the membrane and to target intracellular components. While 
he tryptophan at position 317 of RasGAP domain is essential for 
he antimicrobial activity of TAT-RasGAP 317-326 [9] , the mode of ac- 
ion of this peptide on prokaryotes remains unknown. 
In this report, we questioned the potential effect of TAT- 
asGAP 317-326 on biofilm formation and mature biofilm expansion. 
e show that TAT-RasGAP 317-326 inhibits the formation of A. bau- 
annii, P. aeruginosa and S. aureus biofilms in vitro. Moreover, TAT- 
asGAP 317-326 reduces the expansion of A. baumannii and P. aerug- 
nosa mature biofilms. However, similar to other antibiotics and 
MPs, TAT-RasGAP 317-326 cannot completely eradicate the biofilm 
caffold. These result s highlight the potential of TAT-RasGAP 317-326 
n the prevention and treatment of biofilms and encourage further 
evelopment of AMPs as alternative or combinatory antibiofilm 
reatments. 
. Materials and methods 
.1. Bacterial strains and growth conditions 
Acinetobacter baumannii ATCC 19606 and Staphylococcus aureus 
TCC 29213 were obtained from the American Type Culture Col- 
ection (ATCC, Manassas, VA, USA). Pseudomonas aeruginosa PA14 
as obtained from Prof. Leo Eberl (Department of Plant and Mi- 
robial Biology, University of Zürich, Zürich, Switzerland). Bacte- 
ia were routinely grown in Mueller–Hinton broth ( A. baumannii ), 
ryptic soy broth ( S. aureus ) or Luria–Bertani broth ( P. aeruginosa ). 
.2. Peptides and antibiotics 
TAT-RasGAP 317-326 is composed of amino acids 48–57 of the 
IV TAT protein (RRRQRRKKRG) and 317–326 of the human Ras- 
AP protein (DTRLNTVWMW) linked with two glycines. TAT- 
asGAP 317-326 was synthesised as a retro-inverso d -amino acid 
eptide by SBS Genetech (Beijing, China). Ciprofloxacin, tetracy- 
line and gentamicin were from AppliChem (Darmstadt, Germany), 228 olymyxin B was from Sigma-Aldrich (Saint Louis, MO, USA) and 
elittin was from Enzo Life Sciences (Farmingdale, NY, USA). 
.3. Minimum inhibitory concentration (MIC) measurement 
The MICs of antibiotics and AMPs on bacterial strains were de- 
ermined as described previously [9] . Briefly, overnight cultures 
ere diluted to an optical density at 600 nm (OD 600 ) of 0.1, were
rown for 1 h at 37 °C with 200 rpm shaking and were diluted 
:200 in 96-well plates containing increasing amounts of antibi- 
tics or AMPs. Plates were then incubated statically for 18 h at 
7 °C. The lowest concentration at which no turbidity was observed 
as determined as the MIC. 
.4. Biofilm formation assay and treatment 
Overnight cultures of bacteria were diluted 1:50 and were 
rown to exponential phase at 37 °C. Cultures were washed with 
hosphate-buffered saline (PBS) and adjusted to OD 600 = 0.1 (10 7 –
0 9 CFU/mL) in BM2 medium [62 mM potassium phosphate buffer, 
 mM ammonium sulfate, 10 μM iron sulfate, 0.4% (w/v) glu- 
ose, 0.5% (w/v) casamino acids, 2 mM magnesium sulfate] with or 
ithout antibiotics or AMPs. Then, 100 μL of culture was plated in 
olypropylene plates (Greiner, Kremsmünster, Austria) and biofilms 
ere allowed to form for 24 h ( A. baumannii and P. aeruginosa ) or
8 h ( S. aureus ) at room temperature (RT). For biofilm eradication, 
ature biofilms were washed twice with PBS and were incubated 
ith antibiotics or AMPs in BM2 medium for 24h at RT. 
.5. Measurement of biofilm biomass and bacterial viability 
To assess total biofilm biomass, biofilms were washed with 
ater and stained with 0.1% crystal violet (Sigma-Aldrich) as de- 
cribed previously [11] . Stained biofilms were dried overnight at RT 
nd were dissolved in 30% acetic acid. Absorbance was measured 
t 590 nm. To assess bacterial viability, biofilms were washed 
ith PBS and incubated with 4 μg/mL resazurin (Sigma-Aldrich) 
n BM2. Plates were incubated for 90 min at 37 °C. Fluorescence 
as measured with a FLUOstar® Omega Microplate Reader (BMG 
abtech, Ortenberg, Germany) with excitation/emission wavelength 
f 540/580 nm. 
.6. Calculations 
The lowest concentration of antibiotic or AMP that reduced 
iofilm formation (viability and biomass) by ≥90% was defined 
s the biofilm prevention concentration (BPC 90 ). The minimum 
iofilm inhibitory concentration (MBIC) was defined as the concen- 
ration of antibiotic or AMP that resulted in no expansion of an ex- 
sting biofilm (viability lower and biomass equal to or lower than 
he value at treatment). The minimum biofilm eradication concen- 
ration (MBEC 90 ) was defined as the concentration of antibiotic or 
MP that reduced the biofilm initial biomass by ≥90% upon treat- 
ent. All calculations were adapted from Macià et al. [12] . 
. Results 
.1. Classical antibiotics have a moderate effect on Acinetobacter 
aumannii and Pseudomonas aeruginosa biofilms 
Acinetobacter baumannii and P. aeruginosa form biofilms that 
how increased resistance to antibiotics compared with planktonic 
acteria [13] . We first tested whether this observation could be 
onfirmed using our experimental settings by determining the in- 
ibitory potential of antibiotics on planktonic bacteria (MIC) and 
n bacteria in biofilm formation (BPC ). For A. baumannii , we 90 
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Table 1 
Minimum inhibitory and eradication concentrations of classical antibiotics and antimicrobial peptides (AMPs) 
Antibiotic/AMP MIC ( μg/mL) BPC 90 ( μg/mL) MBIC ( μg/mL) resazurin/CV 
a MBEC 90 ( μg/mL) (% eradication) 
b 
Acinetobacter baumannii ATCC 19606 
Ciprofloxacin 1 > 256 > 256 > 256 ( < 10%) 
Tetracycline 1 128–256 > 256 > 256 ( < 10%) 
Gentamicin 32 > 256 > 256 > 256 ( < 10%) 
TAT-RasGAP 317-326 8 16–32 64/32 > 256 (61%) 
Polymyxin B 4 8–16 32/64 > 256 (30%) 
Melittin 16 16–32 128/64 > 256 (88%) 
Pseudomonas aeruginosa PA14 
Ciprofloxacin 0.2 0.2–0.4 < 2/ > 256 > 256 ( < 10%) 
Tetracycline 16 4–8 32/ > 256 > 256 ( < 10%) 
Gentamicin 4 8 32/ > 256 > 256 (20%) 
TAT-RasGAP 317-326 32 16–32 64 > 256 (60%) 
Polymyxin B 2 4 32 > 256 (65%) 
Melittin 64 128 > 256 > 256 ( < 10%) 
Staphylococcus aureus ATCC 29213 
Ciprofloxacin 0.4 > 256 > 256/32 > 256 (57%) 
Gentamicin 8 > 256 > 256/64 > 256 (10%) 
TAT-RasGAP 317-326 128 128 to > 256 > 256 > 256 ( < 10%) 
Melittin 32 32 64 > 256 ( < 10%) 
MIC, minimum inhibitory concentration; BPC, biofilm prevention concentration; MBIC, minimum biofilm inhibitory concentration; 
CV, crystal violet; MBEC, minimum biofilm eradication concentration. 
a For MBIC, the indication of a single value means that the result was the same with resazurin and CV assays. 







































































easured a robust increase in bacterial resistance towards the 
ested antibiotics (BPC 90 up to > 256 times the MIC of planktonic 
acteria) ( Table 1 ). The effect was less striking for P. aeruginosa 
ith a BPC 90 /MIC ratio of 2 for ciprofloxacin and gentamicin and 
.25 for tetracycline ( Table 1 ). 
In a further step, we tested whether these antibiotics could 
imit biofilm expansion (measuring the MBIC) and eradicate es- 
ablished biofilms (measuring the MBEC 90 ). We used the reduc- 
ion of resazurin to resorufin as a surrogate of bacterial viability 
nd measured total biomass with crystal violet staining. All of the 
ested antibiotics were ineffective both at inhibiting expansion and 
radicating A. baumannii biofilms (MBIC and MBEC 90 , > 256 μg/mL) 
 Table 1 ). While ciprofloxacin, tetracycline and gentamicin limited 
he proliferation of bacteria in P. aeruginosa biofilms at concentra- 
ions corresponding to 2–4 times the BPC 90 , we observed no effect 
n biomass ( Table 1 ). These results confirm the low efficiency of 
lassical antibiotics on biofilms. 
.2. TAT-RasGAP 317-326 potently inhibits the formation and expansion 
f Acinetobacter baumannii and Pseudomonas aeruginosa biofilms 
A number of AMPs and their derivatives were reported to re- 
uce biofilm formation and to degrade existing bacterial biofilms, 
ighlighting an antibiofilm effect for AMPs [14] . Using the model 
MPs melittin and polymyxin B, we observed a consistent in- 
ibitory effect on A. baumannii and P. aeruginosa biofilm formation. 
he BPC 90 of melittin was equal to twice the MIC for A. bauman- 
ii biofilms and 2–4 times higher than the MIC for P. aeruginosa 
iofilms ( Table 1 ). For polymyxin B, the BPC 90 /MIC ratios were 2–4
nd 2 for A. baumannii and P. aeruginosa , respectively ( Table 1 ). As
AT-RasGAP 317-326 is efficient against planktonic A. baumannii and 
. aeruginosa [9] , we hypothesised that it would also potently in- 
ibit the formation of biofilms. TAT-RasGAP 317-326 inhibited A. bau- 
annii biofilm formation at 16–32 μg/mL, corresponding to 1–2 
imes the MIC ( Fig. 1 ; Table 1 ). The BPC 90 of TAT-RasGAP 317-326 
n P. aeruginosa biofilms was equal to its MIC (32 μg/mL) ( Fig. 1 ;
able 1 ). 
Since classical antibiotics had little to no effect on established 
iofilms ( Table 1 ), we tested the ability of AMPs to inhibit the ex-
ansion and to eradicate established biofilms. TAT-RasGAP 317-326 
imited the expansion of A. baumannii biofilms with a MBIC/MIC 229 atio of 4–8 ( Fig. 2 ; Table 1 ). Melittin was effective at 4–8 times the
IC, while polymyxin B had an MBIC/MIC ratio of 8–16 ( Table 1 ).
AT-RasGAP 317-326 efficiently inhibited P. aeruginosa biofilm expan- 
ion with an MBIC/MIC ratio of 2 ( Fig. 2 ; Table 1 ). In contrast,
olymyxin B had a higher MBIC/MIC ratio of 16, while the MBIC 
f melittin could not be determined, being > 256 μg/mL ( Table 1 ).
one of the tested AMPs eradicated > 90% of the biomass of A. 
aumannii and P. aeruginosa biofilms. However, they still induced a 
tronger biomass reduction at the maximum tested concentration 
f 256 μg/mL compared with antibiotics ( Table 1 ). 
.3. TAT-RasGAP 317-326 inhibits the formation of Staphylococcus 
ureus biofilms 
TAT-RasGAP 317-326 is effective both on Gram-negative and 
ram-positive bacteria in planktonic cultures [9] . We thus tested 
ts impact on S. aureus biofilms. Despite the high MIC of TAT- 
asGAP 317-326 on planktonic S. aureus (128 μg/mL), we could mea- 
ure a BPC 90 /MIC ratio of 1–2 by resazurin reduction ( Table 1 ;
ig. 1 ). In comparison, the BPC 90 /MIC ratio of melittin was 0.5–
, while none of the tested antibiotic prevented biofilm formation 
BPC 90 > 256 μg/mL) ( Table 1 ). However, the MBIC and MBEC 90 
f TAT-RasGAP 317-326 on S. aureus biofilm could not be estimated, 
eing > 256 μg/mL. It has to be noted that S. aureus formed appar- 
ntly weaker biofilms than P. aeruginosa and A. baumannii (staining 
ith crystal violet being strongly reduced) ( Fig. 1 B; Fig. 2 B) leading
o high variability in the results. 
. Discussion 
Bacterial biofilms cause nosocomial infections and underlie sev- 
ral chronic infections. The complex structure of biofilms renders 
hem refractory to treatments with classical antibiotics. Here we 
how that the AMP TAT-RasGAP 317-326 has a potent inhibitory ef- 
ect on A. baumannii, P. aeruginosa and, to a lesser extent, S. aureus 
iofilm formation and expansion. These observations support the 
otential use of AMPs as alternatives to classical antibiotics in an- 
ibiofilm treatment. 
To test the quality of the biofilm produced in vitro, we mea- 
ured its resistance to classical antibiotics. As reported in the lit- 
rature, we observed increased resistance of A. baumannii and P. 
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Fig. 1. TAT-RasGAP 317-326 inhibits biofilm formation. The effect of TAT-RasGAP 317-326 on Acinetobacter baumannii, Pseudomonas aeruginosa and Staphylococcus aureus biofilm 
formation was assessed by (A) resazurin reduction and (B) crystal violet assays to measure bacterial viability and biofilm biomass, respectively. Dotted lines indicate 10% of 
initial signal. Data are the mean ± SEM of three experiments performed in quadruplicate. 
Fig. 2. TAT-RasGAP 317-326 reduces biofilm expansion. TAT-RasGAP 317-326 was added to mature biofilms of Acinetobacter baumannii, Pseudomonas aeruginosa and Staphylococcus 
aureus for 24 h. (A) Bacterial viability was approximated by resazurin reduction assay and (B) biofilm biomass by crystal violet staining. Dotted lines indicate 10% of initial 
signal. Dashed lines indicate values for established biofilms before treatment. Data are the mean ± SEM of three experiments performed in quadruplicate. 
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[  eruginosa biofilms to classical antibiotics compared with plank- 
onic cultures. However, resistance was higher for A. baumannii 
iofilms (up to > 512 times the MIC) than for P. aeruginosa biofilms 
2–4 times the MIC). This difference in biofilm resistance to an- 
ibiotics is possibly caused by a faster resistance development dur- 
ng A. baumannii biofilm formation, partly triggered by the an- 
ibiotics themselves [15] . While antibiotics showed some effect on 
iofilm formation at moderate to high concentrations, they were 
nefficient in inhibiting proliferation or disrupting mature biofilms 
 Table 1 ), as reported previously [16] . This low efficiency of antibi-
tics on biofilms highlights the need for alternative strategies to 
arget these biofilms. 
In contrast to antibiotics, the TAT-RasGAP 317-326 , polymyxin B 
nd melittin AMPs limited both bacterial biofilm formation and 
xpansion. Moreover, they showed a stronger biofilm eradication 
otential compared with antibiotics. Polymyxin B and melittin 
ere already reported to have potent antibiofilm activity against 
. baumannii and P. aeruginosa [ 17 , 18 ]. Our results further sup-
ort the use of AMPs alone or in combination with other drugs 
s a possible alternative for the treatment of biofilm-associated 
nfections. The combination of membrane-targeting AMPs with 
lassical antibiotics may be a valuable way to eradicate biofilm- 
mbedded bacteria. In addition to directly killing bacterial cells, 
MPs may also interact with biofilm matrix component or sig- 
alling molecules, thus weakening the biofilm scaffold and pro- 
oting antibiotic entry. In line, the combination of melittin and 
L-37 with classical antibiotics reduced the corresponding MBEC 
y several fold [19] . In clinical settings, several studies reported 
he combination of polymyxin B with classical antibiotics for the 
reatment of MDR bacterial infections, including chronic possibly 
iofilm-mediated infections, with promising results [20] . In future 
tudies, we would like to test the antibiofilm effect of combina- 
ions of TAT-RasGAP 317-326 with classical antibiotics. Indeed, TAT- 
asGAP 317-326 might have advantages compared with other AMPs: 
ts low toxicity to mammalian cells [9] , and its chimeric and syn- 
hetic nature that should avoid selection of pre-existing resis- 
ance and lower the risk of immune response alteration. Moreover, 
ince biofilms are often composed of multiple bacterial species, 
he broad-spectrum antimicrobial activity of TAT-RasGAP 317-326 
s also an attractive feature. While the current version of TAT- 
asGAP 317-326 showed low bioavailability [9] , it could have a potent 
ffect on the treatment of biofilm-associated infections when ad- 
inistrated locally or as implant-covering agent. Furthermore, po- 
ential modifications such as addition of positive charges, addition 
f lipid moieties, or amino acid modifications might improve the 
ioavailability of this peptide and thus increase its efficiency. Nev- 
rtheless, combinations of TAT-RasGAP 317-326 with classical antibi- 
tics or other AMPs might cause synergism against biofilms and 
ould lead to development of combinatory treatments. 
In summary, we show that the AMP TAT-RasGAP 317-326 has 
otent antibiofilm activity in vitro against A. baumannii and P. 
eruginosa and, to a lesser extent, S. aureus biofilms. This makes 
AT-RasGAP 317-326 a promising tool in the treatment of biofilm- 
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